人福医药(600079.SH)：二甲磺酸利右苯丙胺胶囊药品上市许可申请获受理

Core Viewpoint - The company, Renfu Pharmaceutical, has received approval from the National Medical Products Administration for the marketing authorization of Dextroamphetamine Sulfate Capsules, which is used to treat ADHD and moderate to severe binge eating disorder [1] Group 1: Company Information - Renfu Pharmaceutical holds an 80% stake in its subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. [1] - The original research for Dextroamphetamine Sulfate Capsules was first approved in the United States [1] Group 2: Product Information - Dextroamphetamine Sulfate Capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients aged 6 years and older [1] - The product is also indicated for the treatment of moderate to severe Binge Eating Disorder (BED) in adults [1]